|
US6528640B1
(en)
*
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
|
US6482932B1
(en)
*
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
|
US6617438B1
(en)
*
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
|
US20030124513A1
(en)
*
|
2001-05-29 |
2003-07-03 |
Mcswiggen James |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
WO2003034985A2
(fr)
*
|
2001-10-22 |
2003-05-01 |
University Of Rochester |
Interference par telomerase
|
|
AU2003215161A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
AU2003213005A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2108707A3
(fr)
*
|
2002-05-17 |
2010-04-14 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Identification moléculaire d'espèces d'Aspergillus
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
US7618948B2
(en)
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
|
US7829694B2
(en)
*
|
2002-11-26 |
2010-11-09 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
FR2848573B1
(fr)
*
|
2002-12-13 |
2005-04-08 |
Exonhit Therapeutics Sa |
Compositions et methodes pour la detection et le traitement de pathologies neurodegeneratives
|
|
US7994149B2
(en)
|
2003-02-03 |
2011-08-09 |
Medtronic, Inc. |
Method for treatment of Huntington's disease through intracranial delivery of sirna
|
|
US7846906B2
(en)
|
2003-02-28 |
2010-12-07 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US7803781B2
(en)
*
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
WO2004083432A1
(fr)
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation de la reconnaissance d'exons dans le pre-arnm par interference avec la structure d'arn secondaire
|
|
CA2561565C
(fr)
*
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methodes de repression du gene phospholamban et de modulation de la contractilite cardiaque
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
AU2005315143B2
(en)
*
|
2004-12-14 |
2011-05-26 |
National Institute Of Immunology |
Dnazymes for inhibition of Japanese Encephalitis Virus replication
|
|
US8802840B2
(en)
|
2005-03-08 |
2014-08-12 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
|
ES2647452T3
(es)
|
2006-08-08 |
2017-12-21 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Estructura y uso de oligonucleótidos 5' fosfato
|
|
US9375440B2
(en)
|
2006-11-03 |
2016-06-28 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
HUE028662T2
(en)
|
2007-10-26 |
2016-12-28 |
Academisch Ziekenhuis Leiden |
Preparations and methods for controlling muscle disorders
|
|
EP2119783A1
(fr)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
WO2010123369A1
(fr)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucléotide comprenant une inosine pour traiter une dystrophie musculaire de duchenne (dmd)
|
|
CN102762215A
(zh)
|
2009-10-16 |
2012-10-31 |
葛兰素集团有限公司 |
Hbv反义抑制剂
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
WO2012066549A1
(fr)
|
2010-11-15 |
2012-05-24 |
Ramot At Tel-Aviv University Ltd. |
Analogues dipeptidiques pour le traitement d'états pathologiques associé à la formation de fibrilles amyloïdes
|
|
EP2508530A1
(fr)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture
|
|
US8658783B2
(en)
|
2011-04-13 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
PT3505528T
(pt)
|
2011-04-21 |
2021-02-23 |
Glaxo Group Ltd |
Modulação da expressão do vírus da hepatite b (vhb)
|
|
CA2862628C
(fr)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Oligonucleotides a modulation d'arn dotes de caracteristiques ameliorees pour le traitement de la dystrophie musculaire de duchenne et de becker
|
|
RU2015104103A
(ru)
*
|
2012-07-27 |
2016-09-20 |
Биал - Портела Энд К, С.А. |
Способ синтеза замещенных соединений мочевины
|
|
EP2712870A1
(fr)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Nouveaux ligands de RIG-I et procédés pour les produire
|
|
GB201408623D0
(en)
*
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
DE102015113038B3
(de)
*
|
2015-07-13 |
2017-01-19 |
Simone Kann |
Oligonucleotide und deren Verwendung
|
|
WO2019079195A1
(fr)
*
|
2017-10-16 |
2019-04-25 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Cellules souches mésenchymateuses génétiquement modifiées destinées à être utilisées dans des prothèses cardiovasculaires
|
